S&P 500
(2.11%) 5 087.03 points
Dow J
(1.18%) 39 069 points
Nasdaq
(2.96%) 16 042 points
Oil
(0.55%) $78.34
Gas
(-2.76%) $1.724
Gold
(-0.02%) $2 033.90
Silver
(-0.42%) $22.78
Platinum
(1.94%) 906.90
USD/EUR
(-0.01%) 0.924
USD/NOK
(0.48%) 10.52
USD/GBP
(-0.18%) 0.790
USD/RUB
(1.15%) 93.04

Realtime updates for Daiichi Sankyo Company, [4568.T]

Exchange: JPX Sector: Healthcare Industry: Drug Manufacturers—General
Last Updated22 Feb 2024 @ 01:15

-0.28% ¥ 4 917.00

Live Chart Being Loaded With Signals

Commentary (22 Feb 2024 @ 01:15):

Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment...

Stats
Today's Volume 4.16M
Average Volume 4.44M
Market Cap 9 428.09B
EPS ¥0 ( 2024-01-30 )
Next earnings date ( ¥8.41 ) 2024-04-24
Last Dividend ¥15.00 ( 2023-03-30 )
Next Dividend ¥0 ( N/A )
P/E 50.63
ATR14 ¥3.20 (0.06%)

Volume Correlation

Long: 0.51 (weak)
Short: 0.41 (neutral)
Signal:(58.987) Neutral

Daiichi Sankyo Company, Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Daiichi Sankyo Company, Correlation - Currency/Commodity

The country flag -0.20
( neutral )
The country flag -0.66
( moderate negative )
The country flag -0.22
( neutral )
The country flag -0.60
( weak negative )
The country flag -0.07
( neutral )
The country flag -0.39
( neutral )

Daiichi Sankyo Company, Financials

Annual 2022
Revenue: ¥1 278.48B
Gross Profit: ¥914.95B (71.57 %)
EPS: ¥56.96
Q3 2023
Revenue: ¥446.93B
Gross Profit: ¥324.58B (72.62 %)
EPS: ¥34.71
Q2 2023
Revenue: ¥375.51B
Gross Profit: ¥280.77B (74.77 %)
EPS: ¥20.86
Q1 2023
Revenue: ¥350.84B
Gross Profit: ¥257.16B (73.30 %)
EPS: ¥29.74

Daiichi Sankyo Company, Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
¥15.00
(N/A)
¥0
(N/A)
¥15.00
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)

Daiichi Sankyo Company, Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.17 - Stable (23.44%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend ¥4.08 2000-03-28
Last Dividend ¥15.00 2023-03-30
Next Dividend ¥0 N/A
Payout Date 0000-00-00
Next Payout Date
# dividends 46 --
Total Paid Out ¥443.25 --
Avg. Dividend % Per Year 0.00% --
Score 4.46 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 6.17
Div. Directional Score 10.00 --
Next Divdend (Est)
(2024-08-05)
¥0 Estimate 0.00 %
Dividend Stability
0.09 Very Bad
Dividend Score
4.46
Pay Frequency
Semi-Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
8089.T No Dividend Player 2023-09-28 Annually 0 0.00%
7447.T Ex Dividend Knight 2023-08-30 Annually 0 0.00%
6715.T Ex Dividend Junior 2024-03-28 Annually 0 0.00%
6093.T Ex Dividend Knight 2024-02-28 Annually 0 0.00%
4820.T Ex Dividend Knight 2023-12-28 Semi-Annually 0 0.00%
4051.T Ex Dividend Knight 2023-09-28 Annually 0 0.00%
3284.T Ex Dividend Junior 2023-09-28 Semi-Annually 0 0.00%
2335.T Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
9503.T Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
8537.T Ex Dividend Junior 2023-09-28 Semi-Annually 0 0.00%

Daiichi Sankyo Company,

Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.

AboutLive Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators